web analytics
July 27, 2016 / 21 Tammuz, 5776

Posts Tagged ‘Mexico’

Trump May Come to Israel in July to Visit the Southern Wall

Thursday, June 2nd, 2016

Donald Trump is planning to visit Israel before the Republican national convention in July, according to persistent reports, although his campaign is denying it. New York Magazine on Wednesday cited four sources who say Trump’s Jewish son-in-law, Jared Kushner, together with associates of Sheldon Adelson are working on the trip. Trump was planning to visit Israel before the start of the primaries and was hoping for Netanyahu’s endorsement, but then Bibi said he wasn’t planning to endorse anyone. Perhaps the fact that Adelson is involved this time around means that the Israeli PM will at least give the candidate the royal treatment he expects.

“This is a typical time frame when a general-election candidate has an opportunity to flex his foreign-policy muscles,” a Trump staffer told NY Mag.

Some Internet news sources have suggested that Trump may be coming to Israel not for the endorsements, and not to gain favor with the hard-line pro-Israel crowd—he’s got them already. Instead, Trump is going to see the wall. Not the Western Wall, but the 150 mile fence Israel has erected along its border with Egypt, which caused the number of illegal African migrant workers getting through to drop from thousands to single digits annually.

Jewish Insider quoted Trump’s recent book “Crippled America,” where he states, “Walls work. The Israelis spent $2 million per kilometer to build a wall – which has been hugely successful in stopping terrorists from getting into the country. Ironically, some of the same people who claim we shouldn’t build a wall cite the success of Israel’s wall. While obviously we don’t face the same level of terrorist threat as our closest Middle East ally, there is no question about the value of a wall in the fight against terrorism.”

The Negev security fence, which is supported by a heavy military detail, has also been remarkably effective at preventing the ISIS affiliates in the Sinai from infiltrating. Of course, Israel did not ask Egypt to pay for the wall, the way Trump promises to do with Mexico, and the US southern border is not 150 but 1,989 miles. Otherwise, though, Trump could gain points by pointing to the Israeli approach to sealing the border and smiling victoriously in the desert sun.

Of course, if liberal folks live up to their word and flee to Canada after a Trump win, Israel could be cashing in on its border fence technology from two countries.

David Israel

Israel’s Material Well-Being and National Wealth Stats Up Across the Board

Wednesday, May 4th, 2016

Real national disposable income per capita in Israel has gone up by 1.7% in 2014 compared with the year before, reaching a level of 119% compared with the year 2000, Israel’s Central Board of Statistics announced on Wednesday.

In 2014, the government debt as a percentage of GDP (65%) was lower than that of France (85%), Spain (88%), the UK (94%), the US (98%), and Italy (127%). It was higher than Germany’s (48%), the Czech Republic (46%), Sweden (44%), Turkey (37%), Switzerland (21%), and Norway (17%).

Between the years 2008-2011 there was a moderate rise in net income inequality in Israel (according to the Gini coefficient, a.k.a. the Gini index or Gini ratio — a measure of statistical dispersion intended to represent the income distribution of a nation’s residents, which is the most commonly used measure of inequality.) It was followed by a downward trend in the Gini index until 2013, but remains high in Israel, compared with other OECD countries — higher than the US, Turkey, Mexico and Chile.

In 2013, the net annual income per standard capita was 91,604 shekel ($24,283), a rise of 5% compared with the year before, in 2013 rates. The net annual reported income per standard capita in Jewish households was double the amount in Arab households.

In 2013, Israel’s household debt as a percentage of GDP (47%) was significantly lower than most other OECD countries, such as Spain (79%), France (63%), Germany (56%), and Italy (49%). It was still higher than that of Poland (35%), Slovakia (32%), and Hungary (31%).

58% of Israelis ages 20 and up were satisfied with their economic situation in 2014: 59% of men, 57% of women.

Israeli Jews were more satisfied than Israeli Arabs — 60% vs. 48% respectively.

JNi.Media

Smugglers’ Cross-Border Tunnel Discovered in San Diego

Thursday, April 21st, 2016

It’s not only Israel contending with tunnels, although for Israel tunnels pose an existential threat.

For the third time this month, a cross-border tunnel was discovered Wednesday (April 20) leading from Mexico to California. Authorities seized seven tons of marijuana and more than a ton of cocaine.

The tunnel, measuring nearly half a mile, is believed to be the longest ever found in California. It was equipped with a rail system, ventilation, lights and a large elevator, making delivery of the smuggled goods much easier and more efficient. Some tunnels along the U.S.-Mexico border have been discovered with hydraulic lifts and electric rail cards, according to Fox News.

The exit on the U.S. side was about three feet wide. Six people were arrested last Friday in San Diego and charged with constructing tunnels and other drug-related crimes. They were not identified and their affiliation is not known.

There are numerous drug cartels doing “business” throughout Latin America, including a number who carry out transactions with Lebanon’s Iranian-backed Hezbollah terrorist organization.

Agents found 1,600 pounds of marijuana inside the tunnel. Another 11,000 pounds of cannabis and 2,242 pounds of cocaine were found in the truck that had been collected from the handy trash bin strategically placed to hide the mouth of the tunnel, as a pickup site for smugglers. In addition, another 1,430 pounds of marijuana were found in the bin.

Hana Levi Julian

Weizmann Institute Drug Approved for Prostate Cancer Therapy in Mexico

Tuesday, January 5th, 2016

(JNi.media) A therapy invented at the Weizmann Institute of Science and clinically developed in collaboration with Steba Biotech (Luxembourg) has been approved by Cofepris, Mexico’s health authority, for the focal treatment of early-stage prostate cancer.

The therapy involves a laser and a novel drug, TOOKAD® Soluble. A successful Phase III clinical trial in Latin America (Mexico, Peru and Panama), involving 80 patients, confirmed the high rate of local cures and minimal side effects already reported in Phase II clinical trials, as evidenced by negative biopsies and maintenance of patients’ potency, continence and overall quality of life.

The marketing approval in Mexico comes in the wake of the recent completion of a second Phase III clinical trial in Europe. This randomized pivot study compared disease progression, cancer-free rate and urinary and erectile functions in patients treated with TOOKAD® Soluble and those undergoing active surveillance with a follow-up of two years. It involved more than 400 patients at 43 hospitals in 11 European countries and is currently under evaluation by the European Medicines Agency (EMA).

The approved therapy follows a new paradigm developed by Prof. Yoram Salomon of the Biological Regulation Department and Prof. Avigdor Scherz of the Plant and Environmental Sciences Department in the framework of photodynamic therapy. It comprises an intravenous infusion of TOOKAD® Soluble, immediately followed by near-infrared laser illumination through thin optic fibers that are inserted into the cancer prostatic tissue, under ultrasound control. Tookad® Soluble was first synthesized in Scherz’s lab from bacteriochlorophyll, the photosynthetic pigment of certain aquatic bacteria that draw their energy supply from sunlight. The drug stays in the patient’s blood circulation until it totally clears 3-4 hours later, and it shows no toxicity. Confined illumination of the diseased tissue activates the circulating drug locally, resulting in the extensive generation of short-lived toxic molecules: oxygen and nitric oxide radicals. These highly reactive molecules initiate rapid occlusion and destruction of the tumor blood vessels, followed by necrotic death of the entire tumor while sparing nearby structures and their functions. The use of near-infrared illumination, together with the rapid clearance of the drug from the body and the unique non-thermal mechanism of action, makes it possible to safely treat large, deeply embedded cancerous tissue using a minimally invasive procedure. The recent marketing approval was provided to both the drug (TOOKAD® Soluble) and the laser illumination device (Laser), together designated Vascular Targeted Photodynamic Therapy (VTP) with TOOKAD® Soluble.

In the currently approved focal therapy setting, TOOKAD® Soluble VTP (TS-VTP) is a day-case procedure lasting approximately 90 minutes. Patients are released a few hours later and can return to normal activities within a few days, with none of the side effects frequently associated with prostate removal by surgery or radiotherapy. This new minimally invasive technology offers a good alternative to patients diagnosed with early-stage prostate cancer. The number of these patients has dramatically increased in the last two decades due to widespread screening relying on levels of prostate specific antigen (PSA). This population faces the dilemma of undergoing the radical treatment of prostate removal with the risk of high morbidity, or remaining under active surveillance with increased risk of further cancer progression.

Tookad® Soluble answers an unmet need in providing this category of patients with an appropriate treatment, which combines good efficacy with a preservation of the quality of life.

Weizmann institute and Steba Biotech are currently pursuing an extensive oncological research program in collaboration with several clinical groups at Memorial Sloan Kettering Cancer Center in New York City. Four clinical studies for more advanced prostate cancer and other oncological indications stemming from this research are scheduled to start in 2016.

JNi.Media

At Least One Jew Will Vote for Trump

Thursday, July 23rd, 2015

Donald Trump is guaranteed of at least one Jewish vote.

He is Michael Cohen, who is one of Trump’s executives and who serves as his special advisor in the circus act that the Republican party calls a presidential campaign.

Cohen spends a lot of his time defending Trump, whose fame has skyrocketed as America’s most famous bigot since Archie Bunker.

Didn’t Trump say?

When Mexico sends its people, they’re not sending the best. They’re not sending you, they’re sending people that have lots of problems and they’re bringing those problems. They’re bringing drugs, they’re bringing crime. They’re rapists and some, I assume, are good people, but I speak to border guards and they’re telling us what we’re getting.

Cohen reassured CNN last week that The Donald “has a great relationship with Latinos” and also maintained:

[Trump] “never made any derogatory or disparaging remarks about Mexican immigrants.

According to the Forward, Cohen voted for Barack Obama in 2008.

He now is Trumps assured Jewish voter.

Trump may even get a second Jewish vote in the primaries, but it is safe bet he or she will not be a Mexican Jew.

Tzvi Ben-Gedalyahu

Israel, Mexico, Sign Research & Development Pact

Tuesday, December 9th, 2014

Israel and Mexico have signed a deal to cooperate on industrial research and development, Israel’s Ministry of Economy announced Monday.

The two nations are set to fund joint projects aimed at advancing industrial development between both.

Leading fields for cooperation with Mexico will focus primarily on water management, desert agriculture, pharmacology and medical devices, electronics and communication.

“Mexico is one of the world’s largest manufacturers in a variety of fields, comprising an essential part of the country’s economy,” said Rona Kotler Ben Aroya, trade attache to Mexico from the Israeli Ministry of Economy.

“The signing of the industrial R&D agreement between Israel and Mexico will help Israeli companies integrate products and advanced technologies with local manufacturers and realize the potential of [the North American] market.”

Hana Levi Julian

Carnival Cruise Passenger In On-Board Ebola Quarantine

Sunday, October 19th, 2014

A Texas lab technician is in voluntary quarantine aboard a Carnival Cruise ship after the CDC issued a travel ban on workers from Texas Health Presbyterian Hospital Dallas who were near where Ebola patient Thomas Eric Duncan died.

The technician on the cruise ship handled fluids from the dead Ebola patient.

The new CDC requirements are that suspected carriers are banned from planes, trains, ships, bars, restaurants, stores, theaters, and other public locations for a period of 21 days from their last contact.

The technician will be at day 21 on Sunday, and she is currently quarantined in the room with her husband and is showing no symptoms of the disease.

The cruise ship, with 4000 passengers, was set to dock in Mexico, but the country refused to let the ship dock.

The ship was able to let the passengers, except the possibly infected passenger, disembark in Belize and is returning to Texas, where it will arrive on Sunday.

In addition, Dallas nurse, Nina Pham (26) has been diagnosed with Ebola, and is in fair condition and being treated.

While another Dallas nurse, Amber Vinson (29), who was infected with Ebola, flew on a plane between Dallas and Cleveland. She is hospitalized in stable condition. She was flying out to plan her upcoming wedding.

Both nurses treated Thomas Eric Duncan at Texas Health Presbyterian Hospital.

Jewish Press News Briefs

Printed from: http://www.jewishpress.com/news/breaking-news/carnival-cruise-passenger-in-on-board-ebola-quarantine/2014/10/19/

Scan this QR code to visit this page online: